At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 910 enrolled
Drug / intervention
Atogepant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)
In Brief
A Phase 3 clinical trial evaluating Atogepant and Placebo for Episodic Migraine. Completed, enrolled 910 participants across 138 sites.
Detailed Summary
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpisodic Migraine
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedDec 2018
Primary CompletionJun 2020
TodayJul 2026
First PostedDec 17, 2018
Enrollment StartDec 14, 2018
Primary CompletionJun 19, 2020
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 7.5 years ago
Interventions
Atogepantdrug
Atogepant tablet
Placebodrug
Placebo-matching atogepant tablets